It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Caspase-6 is a cysteine protease that plays essential roles in programmed cell death, axonal degeneration, and development. The excess neuronal activity of Caspase-6 is associated with Alzheimer disease neuropathology and age-dependent cognitive impairment. Caspase-6 inhibition is a promising strategy to stop early stage neurodegenerative events, yet finding potent and selective Caspase-6 inhibitors has been a challenging task due to the overlapping structural and functional similarities between caspase family members. Here, we investigated how four rare non-synonymous missense single-nucleotide polymorphisms (SNPs), resulting in amino acid substitutions outside human Caspase-6 active site, affect enzyme structure and catalytic efficiency. Three investigated SNPs were found to align with a putative allosteric pocket with low sequence conservation among human caspases. Virtual screening of 57,700 compounds against the putative Caspase-6 allosteric pocket, followed by in vitro testing of the best virtual hits in recombinant human Caspase-6 activity assays identified novel allosteric Caspase-6 inhibitors with IC50 and Ki values ranging from ~2 to 13 µM. This report may pave the way towards the development and optimisation of novel small molecule allosteric Caspase-6 inhibitors and illustrates that functional characterisation of rare natural variants holds promise for the identification of allosteric sites on other therapeutic targets in drug discovery.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Jewish General Hospital, Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Quebec, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); McGill University, Department of Neurology and Neurosurgery, Quebec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
2 Université de Montréal, Institute for Research in Immunology and Cancer, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 Jewish General Hospital, Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Quebec, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); McGill University, Department of Anatomy and Cell Biology, Quebec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
4 McGill University, Department of Biochemistry, Quebec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
5 McGill University, Department of Physiology and Biochemistry, Québec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
6 Jewish General Hospital, Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Quebec, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); McGill University, Department of Neurology and Neurosurgery, Quebec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Department of Anatomy and Cell Biology, Quebec, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)